{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:49:07Z","timestamp":1793638147209,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":100,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.jtauto.2022.100156","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T11:38:01Z","timestamp":1650109081000},"page":"100156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-4062","authenticated-orcid":false,"given":"Piyu Parth","family":"Naik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2022.100156_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid","volume":"145","author":"Egami","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","article-title":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus","volume":"103","author":"Yamagami","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jtauto.2022.100156_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.481","article-title":"Specific Btk inhibition suppresses B cell-and myeloid cell-mediated arthritis","volume":"7","author":"Di Paolo","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jtauto.2022.100156_bib5","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"10.1016\/j.jtauto.2022.100156_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1124\/jpet.111.187740","article-title":"RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jtauto.2022.100156_bib7","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","article-title":"Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models","volume":"202","author":"Haselmayer","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2022.100156_bib9","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015339","article-title":"Immunology and skin in health and disease","volume":"4","author":"Richmond","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jtauto.2022.100156_bib10","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Singh","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jtauto.2022.100156_bib11","series-title":"Calquence (Acalabrutinib) Prescribing Information AstraZeneca Pharm. LP, AstraZeneca Pharmaceuticals","author":"P","year":"2019"},{"key":"10.1016\/j.jtauto.2022.100156_bib12","series-title":"IMBRUVICA (Ibrutinib) Prescribing Information","author":"LLC","year":"2019"},{"key":"10.1016\/j.jtauto.2022.100156_bib13","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jtauto.2022.100156_bib14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0030-4220(74)90365-X","article-title":"Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion, Oral Surg","volume":"38","author":"Pisanti","year":"1974","journal-title":"Oral Med. Oral Pathol."},{"key":"10.1016\/j.jtauto.2022.100156_bib15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2340\/00015555-2706","article-title":"Pemphigus vulgaris and pemphigus foliaceus: differences in epidemiology and mortality","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jtauto.2022.100156_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archderm.1980.01640330073017","article-title":"Pemphigus in hartford county, Connecticut, from 1972 to 1977","volume":"116","author":"Simon","year":"1980","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.jtauto.2022.100156_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jdv.15227","article-title":"Investigation of the predisposing factor of pemphigus and its clinical subtype through a genome-wide association and next generation sequence analysis","volume":"33","author":"Sun","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jtauto.2022.100156_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-4632.2005.02038.x","article-title":"HLA-DRB1*0101 is associated with foliaceous pemphigus in Mexicans","volume":"44","author":"del Mar S\u00e1ez-de-Ocariz","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib20","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2016.1152888","article-title":"The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy","volume":"12","author":"Crofford","year":"2016","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevImmunol.2018025184","article-title":"The role of bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity","volume":"38","author":"Rip","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00034-18","article-title":"Organization of the skin immune system and compartmentalized immune responses in infectious diseases","volume":"32","author":"Quaresma","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jtauto.2022.100156_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/ar3400","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells","volume":"13","author":"Chang","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jtauto.2022.100156_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/ITT.S240874","article-title":"Bruton's tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE?","volume":"9","author":"Lorenzo-Vizcaya","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.jtauto.2022.100156_bib25","series-title":"Efficacy in Collagen Induced Arthritis Models with a Selective, Reversible Covalent Brutons Tyrosine Kinase Inhibitor PRN473 Is Driven by Durable Target Occupancy rather than Extended Plasma Exposure (THER5P. 904)","author":"Bisconte","year":"2015"},{"key":"10.1016\/j.jtauto.2022.100156_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bph.14090","article-title":"PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen 1 signalling","volume":"175","author":"Herter","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jtauto.2022.100156_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/vde.12841","article-title":"Efficacy of a Bruton's tyrosine kinase Inhibitor (PRN 473) in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","volume":"394","author":"Schmidt","year":"2019","journal-title":"Pemphigus, Lancet"},{"key":"10.1016\/j.jtauto.2022.100156_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-017-8662-z","article-title":"Pemphigus: a comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches","volume":"54","author":"Pollmann","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/15419061.2014.943397","article-title":"150th anniversary series: desmosomes and autoimmune disease, perspective of dynamic desmosome remodeling and its impairments in pemphigus","volume":"21","author":"Kitajima","year":"2014","journal-title":"Cell Commun. Adhes."},{"key":"10.1016\/j.jtauto.2022.100156_bib31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3389\/fimmu.2019.01128","article-title":"Role of Dsg1- and Dsg3-mediated signaling in pemphigus autoantibody-induced loss of keratinocyte cohesion","volume":"10","author":"Walter","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib32","doi-asserted-by":"crossref","first-page":"591971","DOI":"10.3389\/fimmu.2020.591971","article-title":"Milestones in personalized medicine in pemphigus and pemphigoid","volume":"11","author":"Bieber","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100156_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jid.2019.11.005","article-title":"Recent advances in understanding pemphigus and bullous pemphigoid","volume":"140","author":"Hammers","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.jtauto.2022.100156_bib35","doi-asserted-by":"crossref","first-page":"23778","DOI":"10.1074\/jbc.M501365200","article-title":"Desmosome signaling. Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization","volume":"280","author":"Berkowitz","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtauto.2022.100156_bib36","doi-asserted-by":"crossref","first-page":"8936","DOI":"10.1074\/jbc.M109.087999","article-title":"P38MAPK signaling and Desmoglein-3 internalization are linked events in pemphigus acantholysis","volume":"285","author":"Jolly","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtauto.2022.100156_bib37","doi-asserted-by":"crossref","first-page":"12524","DOI":"10.1074\/jbc.M808204200","article-title":"Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtauto.2022.100156_bib38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.jid.5701080","article-title":"Induction of p38MAPK and HSP27 phosphorylation in pemphigus patient skin","volume":"128","author":"Berkowitz","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib39","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib40","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2169\/internalmedicine.0578-17","article-title":"Paraneoplastic pemphigus associated with B-cell chronic lymphocytic leukemia treated with Ibrutinib and rituximab","volume":"57","author":"Ito","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.jtauto.2022.100156_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/CCID.S100802","article-title":"Paraneoplastic pemphigus: a short review","volume":"9","author":"Wieczorek","year":"2016","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.det.2011.06.016","article-title":"Current management strategies in paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome)","volume":"29","author":"Frew","year":"2011","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.jtauto.2022.100156_bib43","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jtauto.2022.100156_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coph.2019.01.001","article-title":"Pharmacological advances in pemphigus","volume":"46","author":"Bilgic Temel","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jtauto.2022.100156_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/vde.12878","article-title":"Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib46","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jtauto.2022.100156_bib47","first-page":"2","volume":"vol. 9","author":"Yuko","year":"2019"},{"key":"10.1016\/j.jtauto.2022.100156_bib48","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1021\/acs.jmedchem.0c00597","article-title":"A fast and clean BTK inhibitor","volume":"63","author":"Gabizon","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jtauto.2022.100156_bib49","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2222.2010.03572.x","article-title":"Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes","volume":"40","author":"MacGlashan","year":"2010","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jtauto.2022.100156_bib50","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin. Transl. Sci."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258990902200017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258990902200017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:36:10Z","timestamp":1762904170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258990902200017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":50,"alternative-id":["S258990902200017X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2022.100156","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2022.100156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100156"}}